Dataset from A Randomized,Double-blind,Parallel-group,Multicentre,Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/Daily or Placebo)With Fulvestrant (Loading Dose)in Postmenopausal Advanced BC Patients
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00007712
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective is to assess the event-free survival defined as the time from
randomisation to progression, death without progression, loss to follow up, whichever
occurred first..
创建时间：
2024-11-26
